FDA has approved Libtayo (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
